PharmaSphere: Early-Stage Technology Transfer Collaborations – Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry

Publisher Name :
Date:30-Apr-2013
No. of pages: 80

PharmaSphere: Early-Stage Technology Transfer Collaborations Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry”" report provides a cross-section of major licensing deals between mid to large-sized pharmaceutical companies and academic and nonprofit research institutions. This report examines the terms, platform technologies, and deal rationale of 25 pharma-academic alliances from 2012–2013. GlobalData’s Industry Dynamics team of analysts discusses the significant macro-environment drivers which are leading to an increase in research partnerships with academic research institutions on behalf of pharmaceutical companies. We also discuss the unsustainability of the current drug research model, and the industry’s attempts at moving toward an open R&D ecosystem.

Highlights

Key Questions Answered

  • What are the reasons for increased activity in strategic deals with academia by leading pharmaceutical companies and promising biotechs?
  • What are the deal terms of these collaboration agreements?
  • What therapeutic areas and geographic markets are pharmaceutical companies targeting to partner with academic research institutions?
  • What proprietary platforms and enabling technologies are these pharmaceutical companies trying to access?

Key Findings

  • With the patent cliff and high R&D costs eroding corporate profitability, pharmaceutical companies will look for ways to replenish their pipelines by reaching out to academia in search of novel drug platforms
  • Despite the FDA approving 39 new drugs in 2012, the innovation gap continues, as many of these medicines are ‘me-too’ drugs, or orphan drugs indicated to treat small segments of the population suffering from rare diseases
  • Difficulty accessing capital and the continued economic recession have led to a deal adverse environment resulting in deals to decline on a global basis
  • Oncology, CNS, immunology and infectious diseases still remain hot therapeutic areas to strike licensing deals with academia

Scope

  • Full examination of 25 significant technology transfer deals from 2012 and 2013 involving large pharmaceutical companies and academic organizations including licensing structure and terms
  • Analysis of the key drivers, trends, and strategies behind the deals undertaken by these pharmaceutical companies across major therapeutic areas
  • Discussion of the unsustainability of the current drug research model and how Big Pharma’s embrace of collaboration and an open ecosystem could drive the next wave of scientific discovery
  • Tech Transfer in Action : Each section of the report includes a number of case studies and to highlight major themes within technology transfer
  • Platform assessment on enabling drug technologies being employed by academic research institutions of interest to pharmaceutical companies
  • Breakdown of disruptive innovation trends, including open-source patient data, pre-competitive information sharing, ‘Big Data’ and drug recycling/repurposing approaches

Key Benefits

  • Analyze and track the strategies that these pharmaceutical companies are using to gain share in an increasingly competitive marketplace
  • Target academic institutions with novel and proprietary technologies to maximize opportunities for strategic investment or partnerships
  • Formulate effective licensing strategies by understanding the various factors and deal terms considered when structuring tech-transfer partnerships
  • Use information as an independent source for your due diligence and transaction strategies

PharmaSphere: Early-Stage Technology Transfer Collaborations – Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry

Table Of Contents

1 Table of Contents 4
1.1 List of Tables 9
1.2 List of Figures 10

2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 12
2.3 About PharmaSphere Report Series 13

3 A Changing and Challenging Deal Making Landscape 14
3.1 Overview 14
3.2 Deal Drivers 15
3.2.1 The Patent Cliff 15
3.2.2 Deal-Adverse Environment 18
3.2.3 Spike in Regulatory Approvals but Innovation Gap Continues 22
3.2.4 FDA’s Proposal to Lower Regulatory Standards in Early-Stage Alzheimer’s Research 23
3.2.5 More Stringent Regulatory Regime in a Post-Vioxx and Avandia World 24
3.2.6 Viewpoint: Vioxx and Avandia Cases 25

4 An Unsustainable R&D Paradigm 27
4.1 Big Pharma’s Embrace of Disruptive Innovation May Fix Broken R&D Model 28
4.1.1 Pre-Competitive Information Sharing 28
4.1.2 Open-Source Patient Data 29
4.1.3 ‘Big Data’ and Drug Discovery 30
4.1.4 Tech Transfer in Action: Astellas Pharma Taps IT for Drug Discovery 31
4.1.5 Drug Recycling 31
4.1.6 Viewpoint: Drug Repurposing at NCATS 32
4.1.7 Tech Transfer in Action: Roche & Broad Join to Bring Failed Drugs Back from the Dead 33

5 Major Global Technology Transfer Alliances 34
5.1 The Bayh-Dole Act of 1980 34
5.2 Deals Overview 36
5.3 Biscayne Pharma Enters into Licensing Agreement with University of Miami for Growth Hormone-Releasing Technology 40
5.3.1 Deal Summary 40
5.3.2 Deal Analysis 40
5.4 Genoa Pharma Enters into Research Agreement with McMaster University for IPF 42
5.4.1 Deal Summary 42
5.4.2 Deal Analysis 42
5.5 AstraZeneca Partners with Vanderbilt University for Neuroscience Drug Discovery 44
5.5.1 Deal Summary 44
5.5.2 Deal Analysis 44
5.6 Trovagene Grants License for NPM1 Marker for AML to Duke University 45
5.6.1 Deal Summary 45
5.6.2 Deal Analysis 45
5.7 Synthetic Biologics and University of Texas Ink Research Deal to Fight Pertussis 47
5.7.1 Deal Summary 47
5.7.2 Deal Analysis 47
5.8 BMS and Vanderbilt University Sign Deal to Develop Drugs for Parkinson’s 49
5.8.1 Deal Summary 49
5.8.2 Deal Analysis 49
5.9 AstraZeneca and Broad Institute Partner to Advance Discovery of Antibacterial and Antiviral Agents 50
5.9.1 Deal Summary 50
5.9.2 Deal Analysis 50
5.10 Bayer HealthCare Opens New Lab Space – The CoLaborator – for Biotech Startups 51
5.10.1 Deal Summary 51
5.10.2 Deal Analysis 51
5.11 Novartis Enters into Licensing Agreement with Penn for CART-19 53
5.11.1 Deal Summary 53
5.11.2 Deal Analysis 53
5.12 Sanofi and BWH Agree to Develop Antibodies for Type 1 Diabetes 55
5.12.1 Deal Summary 55
5.12.2 Deal Analysis 55
5.13 AstraZeneca and Leading Academic Organizations Collaborate on Alzheimer’s Research 56
5.13.1 Deal Summary 56
5.13.2 Deal Analysis 56
5.14 Novo Nordisk Enters into R&D Agreement with JDRF for Type 1 Diabetes 57
5.14.1 Deal Summary 57
5.14.2 Deal Analysis 57
5.15 Large Pharmas Unite with the Genome Institute of Singapore to Combat Cancer in Asian Populations 58
5.15.1 Deal Summary 58
5.15.2 Deal Analysis 58
5.15.3 Tech Transfer in Action: National University Singapore Startup AyoxxA Biosystems 59
5.16 University of Washington and ‘Big Pharma’ Join Forces to Research Drug Transporters 60
5.16.1 Deal Summary 60
5.16.2 Deal Analysis 60
5.17 Pharma and the University of Dundee Create Consortium on Cell Signaling Research 61
5.17.1 Deal Summary 61
5.17.2 Deal Analysis 61
5.18 Novo Nordisk and Oxford Join to Identify Novel Biomarkers for Rheumatoid Arthritis 62
5.18.1 Deal Summary 62
5.18.2 Deal Analysis 62
5.19 Elan Corporation and University of Cambridge Enter into Joint Venture to Discover New Therapies Targeting Neurodegenerative Disorders 63
5.19.1 Deal Summary 63
5.19.2 Deal Analysis 63
5.20 GSK and Yale Partner to Develop New Drugs Targeting Disease-Causing Proteins 64
5.20.1 Deal Summary 64
5.20.2 Deal Analysis 64
5.21 Big Pharma Companies and Research Institutions Tackle Early-Stage Research TB 65
5.21.1 Deal Summary 65
5.21.2 Deal Analysis 65
5.22 Accuray Signs Collaboration Agreement with University of Heidelberg to Provide Cutting-edge Research in Radiation Oncology 66
5.22.1 Deal Summary 66
5.22.2 Deal Analysis 66
5.23 UCB and Oxford University Join to Focus on Developing Innovative Medicines for Immunological and Neurological Disorders 67
5.23.1 Deal Summary 67
5.23.2 Deal Analysis 67
5.24 Large Pharma and King’s College London Establish a Center to Tackle Autism 69
5.24.1 Deal Summary 69
5.24.2 Deal Analysis 69
5.25 Merck Establishes an Independent Non-profit Drug Research Institute – the California Institute for Biomedical Research 70
5.25.1 Deal Summary 70
5.25.2 Deal Analysis 70
5.26 J&J and University of Queensland Develop Drugs Using Spider Venom for Treating Pain 71
5.26.1 Deal Summary 71
5.26.2 Deal Analysis 71
5.27 Sanofi and UCSF Form a Pact to Work on New Treatments for Diabetes 73
5.27.1 Deal Summary 73
5.27.2 Deal Analysis 73
5.27.3 Tech Transfer in Action: Tufts University Spin-off Anchor Therapeutics 74

6 Future Outlook 76

7 Appendix 77
7.1 Research Methodology 77
7.1.1 Coverage 77
7.1.2 Secondary Research 77
7.1.3 Expert Panel Validation 78
7.2 About the Author 78
7.2.1 Analyst 78
7.3 Director, Healthcare Industry Dynamics 79
7.4 Global Head of Healthcare 79
7.5 About the Industry Dynamics Team 79
7.6 GlobalData 80
7.7 Contact Us 80
7.8 Disclosure Information 80
7.9 Disclaimer 80

List Of Tables

Table 1: Recent and Upcoming US Patent Expirations with FY2011 and FY2012 Sales Data 16
Table 2: Deals Summary of Major Technology Transfer Alliances, January 2012–January 2013 38
Table 3: Biscayne Pharma & University of Miami, Deal Summary, 2013 40
Table 4: Genoa Pharma & McMaster University, Deal Summary, 2013 42
Table 5: AstraZeneca & Vanderbilt University, Deal Summary, 2013 44
Table 6: Trovagene & Duke University, Deal Summary, 2012 45
Table 7: Synthetic Biologics & University of Texas, Deal Summary, 2012 47
Table 8: BMS & Vanderbilt University, Deal Summary, 2012 49
Table 9: AstraZeneca & Broad Institute, Deal Summary, 2012 50
Table 10: Bayer HealthCare & Aronora, ProLynx, Deals Summary 2012 51
Table 11: Novartis & University of Pennsylvania, Deal Summary 2012 53
Table 12: Sanofi & Brigham and Women’s Hospital, Deal Summary 2012 55
Table 13: AstraZeneca & Leading Academic Organizations, Deal Summary 2012 56
Table 14: Novo Nordisk & JDRF, Deal Summary 2012 57
Table 15: Eli Lilly, Merck, Pfizer & Genome Institute of Singapore, Deal Summary 2012 58
Table 16: AZ, Genentech, Merck & University of Washington in St. Louis, Deal Summary 2012 60
Table 17: Pharma & University of Dundee, Deal Summary 2012 61
Table 18: Novo Nordisk & University of Oxford, Deal Summary 2012 62
Table 19: Elan Corporation & University of Cambridge, Deal Summary 2012 63
Table 20: GSK & Yale University, Deal Summary 2012 64
Table 21: Pharma & Texas A&M University and Cornell Medical College, Deal Summary 2012 65
Table 22: Accuray & University of Heidelberg, Deal Summary 2012 66
Table 23: UCB & Oxford University, Deal Summary 2012 67
Table 24: Eli Lilly, Janssen, Pfizer, Roche & Kings College London, Deal Summary 2012 69
Table 25: Merck, Pharma & Biotech Start-ups, Deal Summary 2012 70
Table 26: Johnson & Johnson & University of Queensland, Deal Summary 2012 71
Table 27: Sanofi & University of California at San Francisco, Deal Summary 2012 73

List Of Figures

Figure 1: Lipitor Sales WW vs. US, 4Q11–4Q12 15
Figure 2: Pharmaceuticals and Healthcare, Number of Deals and Deal Values (US $m), Globally from September 2012 – February 2013 18
Figure 3: Pharmaceuticals & Healthcare, Number of Deals by Region, February 2013 19
Figure 4: Pharmaceuticals & Healthcare, Number of Deals by Therapy Area, February 2013 20
Figure 5: FDA Drug Approvals, 1995–2012 22
Figure 6: Academic Technology Transfer Deals and Deal Values (US $m), from 2007–2012 36

  • Challenges in the Tourism Industry in Thailand
    Thailand has always been a popular tourist destination and tourism provides a major boost to the country’s economy. Bangkok, Hua Hin, Krabi, Samui, Phuket and Cha Am are some of the most attractive tourist destinations in the country. In 2012, Thailand had a very high number of arrivals. Even the number of Thai citizens who [...]
  • Future of the US Consumer Electronics Market
    The market for consumer electronics has been growing steadily. Some of the factors that are contributing to the growth in the market are technological advancement, rise in disposable income and increasing demand for new products. During 2012, consumer electronics market in the US demonstrated positive expansion, although the growth rate slowed down considerably following the [...]
  • Overview of the Global Retail Market
    The global retail industry continued to grow despite the difficult economic conditions in the world. In the fiscal year of 2011, sales-weighted, currency-adjusted revenue rose by 5.1% to $4.271 trillion for the world’s top 250 retailers. According to GRDI (Global Retail Development Index), in 2013 Brazil occupied the top spot in retail development. Chile and [...]
  • Bright Future Predicted for the Tourism Industry in Singapore
    Travel and tourism industry in Singapore has been growing at a steady rate and is considered to be a major contributor to the economic growth of the country. In 2012, Singapore’s IVA (International Visitors Arrivals) reached a record high of 14.5 million, with a growth rate of 10.1% year-on-year. In recent years, inbound travel to [...]
  • Potential of Staffing Market in United States
    The staffing industry places individuals into contract, temporary and permanent positions in firms around the world. Major staffing markets include France, Spain, Italy and Japan as well as many emerging markets. Temporary staffing around the world has been growing, but in US temporary market has been flat since 2006. The majority of staffing revenue majorly [...]
  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • Chronic Lymphocytic Leukemia (CLL) Treatment Market worth $3.3 billion by 2018
  • New Entrants to Boost Chronic Lymphocytic Leukemia Treatment Market Value to $3.3 Billion by 2018, says GlobalData. The introduction of several new drugs will accelerate growth in the Chronic Lymphocytic Leukemia (CLL) treatment market, from $1.4 billion in 2013 to …

  • Thailand Pharmaceuticals and Healthcare Report Q4 2014
    Published: 20-Aug-2014        Price: US $1295 Onwards        Pages: 115
    BMI View: Thailand offers several revenue earning opportunities to drugmakers due to its ageing population and the presence of a universal healthcare system that provides the population with access to healthcare. However cost containment policies and delays in patent approvals limit the attractiveness of the country to multinational pharmaceutical firms. Headline Expenditure Projections ? Pharmaceuticals: THB142.5bn (USD4.64bn) in 2013 to THB146.5bn (USD4.5bn) in 2014; +2.8% in local currency te......
  • Algeria Pharmaceuticals and Healthcare Report Q4 2014
    Published: 20-Aug-2014        Price: US $1295 Onwards        Pages: 101
    BMI View: The Algerian government's aspirations to rebalance the pharmaceutical trade deficit and promote local generic production, whilst enhancing the country's competitiveness by stimulating the innovative biopharmaceutical industry as a strategic sector in the economy, will continue throughout Q414. A new memorandum of understanding between Pharmaceutical Research and Manufacturers of America (PhRMA) and Algeria's government indicates additional steps towards encouraging foreign direct inves......
  • Zambia Pharmaceuticals and Healthcare Report Q4 2014
    Published: 20-Aug-2014        Price: US $1295 Onwards        Pages: 61
    BMI View: The disparity between urban and rural healthcare provision in Zambia is showing signs of being addressed, with the recent opening of the first ever hospital to serve the district of Chienge. This, along with ongoing governmental training initiatives aimed at improving the skills of Zambian healthcare professionals, is likely to attract talent to the country. That said, speculation over President Sata's ill health, along with delays in the construction of 650 healthcare clinics across t......
  • Australia Pharmaceuticals and Healthcare Report Q4 2014
    Published: 20-Aug-2014        Price: US $1295 Onwards        Pages: 135
    BMI View: Over 300 drug formulations listed on the Pharmaceutical Benefits Scheme (PBS) will be subject to price reduction from October 1 2014, following the first simplified price disclosure (SPD) cycle in Australia. As a result, the prices of the affected drugs will be lowered by 20% on average, from those in April 2014. The Australian government continues to push price controls on pharmaceuticals. This is a reflection of the fact that high prices are no longer accepted by patients and nationa......
  • Croatia Pharmaceuticals and Healthcare Report Q4 2014
    Published: 20-Aug-2014        Price: US $1295 Onwards        Pages: 102
    BMI View: Heavy price cuts and margin restrictions within the pharmaceutical supply chain threaten to cause drug shortages and weaken the supply chain within Croatia, with product withdrawals expected and the HZZO braced for revolt from pharmacies and wholesalers. We forecast weak pharmaceutical market growth over the next decade, in light of Croatia's acceding to EU pressure to rein in its budget deficit. Liquidity issues and payment terms will remain unfavourable in 2014, but with Croatia's ec......
  • Kenya Pharmaceuticals and Healthcare Report Q4 2014
    Published: 20-Aug-2014        Price: US $1295 Onwards        Pages: 106
    BMI View: Investment into Kenya's healthcare sector by pharmaceutical and medical device companies is an advisable business strategy - as highlighted by the high growth forecast in healthcare spending between 2013 and 2018. However, we note that there are downside risks to our forecast, including government inefficiencies and the out-of-pocket characteristics of the market, which will act as challenges for companies looking for a rapid return on investment. Headline Expenditure Projections ? Pha......
  • Latvia Pharmaceuticals and Healthcare Report Q4 2014
    Published: 20-Aug-2014        Price: US $1295 Onwards        Pages: 107
    BMI View: Latvia's macroeconomic environment continues to improve at the same time as smooth transitions to a new currency and new Prime Minister. Market growth forecasts are strong although the country will continue to present a modest opportunity to larger multinational companies on account of its relatively small market size. Meanwhile, tensions between Ukraine and Russia may provide challenges for local manufacturers looking towards exports to Russia to boost revenue. Headline Expenditure Pr......
  • 2014 Market Research Report on Global Seaweed Fertilizer Industry
    Published: 19-Aug-2014        Price: US $3600 Onwards        Pages: 182
    This is a professional and depth research report on Global Seaweed Fertilizer industry. The report firstly introduced Seaweed Fertilizer basic information included Seaweed Fertilizer definition classification application industry chain structure industry overview;Then introduce North America (United States Canada etc) Europe (Ireland UK etc) Asia (China India etc) Rest of World Key players 2009-2014 Seaweed Fertilizer Capacity Production Price Cost Gross Production Value Gross Margin etc Dat......
  • 2014 Market Research Report on Global Glucose Meter Industry
    Published: 19-Aug-2014        Price: US $3600 Onwards        Pages: 321
    This is a professional and depth research report on Global Glucose Meter industry. The report firstly introduced Glucose Meter basic information included Glucose Meter definition classification application industry chain structure industry overview;Then introduce North America (United States Canada Mexico etc) Europe (Germany France United Kingdom Italy Spain etc) Asia (China Japan India Korea etc) Rest of World (Australia South America Middle East and Africa etc) Key players 2009-2014 Gluco......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs